Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient (API) for Roche’s Actemra/RoActemra (tocilizumab), a treatment for rheumatoid arthritis which is also being tested in various clinical trials investigating the safety and efficacy in COVID-19 associated pneumonia.
Under the terms of the initial agreement, the manufacturing process expertise of Roche will be transferred to the Novartis Drug Substance Singapore site during the second quarter this year.
The initial agreement that has been signed covers the technology transfer and the process validation.
Steffen Lang, Head of Novartis Technical Operations and member of the Novartis Executive Committee, said: “Novartis is fully committed to collaborating with Roche in offering our proven biologics production capabilities.
“As one of the world’s largest producers of medicines, Novartis can mobilise its manufacturing capabilities on multiple fronts.”
Actemra/RoActemra has also been approved for the treatment of paediatric juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, giant cell arteritis, and CAR-T cell-induced cytokine release syndrome.
In March, Novartis also announced an initial agreement to manufacture the mRNA and bulk drug product for the COVID-19 vaccine candidate CVnCoV from CureVac, to aid in the fight against the COVID-19 pandemic in their production facility at the Novartis site in Kundl, Austria.
An initial agreement with BioNtech was also signed in January to provide manufacturing capacity for a COVID-19 vaccination at the Novartis site in Stein, Switzerland.
This is a syndicated feed from Pharmafile